> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letter
- URL: https://www.fdaweb.com/latest-fda-warning-letter-27/
- Published: 2019-05-07T12:00:00.000Z
- Updated: 2026-09-15T01:24:54.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144051

FDA has posted its latest batch of Warning Letters that includes one medical product company. It can be accessed by clicking on the link following the summary below:

**Laboratoires Clarins**, Pontoise, France (4/23): FDA inspected the firm 9/2018 and cited significant GMP violations with finished pharmaceuticals. For example, the company failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications. It also failed to establish adequate written procedures for production and process controls. Additionally, Lab Clarins failed to clean, maintain, and sanitize or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, and purity of its drug products. FDA recommended that the company retain a GMP consultant to assist with its compliance.  
[https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratoires-clarins-568157-04232019](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/laboratoires-clarins-568157-04232019?ref=fdaweb.com)